BACKGROUND: Retinopathy of prematurity (ROP) is a potentially blinding, retinal neovascular disease. Systemic prolactin accesses the retina to regulate blood vessels. Prolactin is proangiogenic and can be cleaved to antiangiogenic vasoinhibins. We investigated whether circulating prolactin and vasoinhibins associate with incidence and progression of ROP. METHODS: A prospective, longitudinal, case-control study covering postnatal weeks 1 to 9 measured serum prolactin, vasoinhibins, and vascular endothelial growth factor (VEGF) weekly in 90 premature infants diagnosed as ROP or control. RESULTS: Prolactin levels were higher in ROP than in control patients before (106.2 ± 11.3 (SEM) vs. 64.7 ± 4.9 ng/ml, postnatal week 1) and during (120.6 ± 10 vs. 84.7 ± 7.5ng/ml, postnatal week 5) ROP diagnosis. Prolactin, but not gestational age, birth weight, Apgar score, sepsis, or ventilation time, correlated with ROP. The relative risk (RR) of developing ROP increased if Prolactin (PRL) levels were higher than thresholds of 80 ng/ml (RR = 1.55, 95% CI: 1.06-2.28), 100 ng/ml (RR = 1.63, 95% CI: 1.14-2.34), or 120 ng/ml (RR = 1.95, 95% CI: 1.41-2.68). Vasoinhibin levels were 39.7% higher (95% CI: 4.5-77.5) in the circulation of ROP than in control patients at postnatal week 1 and similar thereafter, whereas VEGF serum levels were always similar. CONCLUSION: High serum prolactin and vasoinhibin levels predict and may impact ROP progression.
BACKGROUND:Retinopathy of prematurity (ROP) is a potentially blinding, retinal neovascular disease. Systemic prolactin accesses the retina to regulate blood vessels. Prolactin is proangiogenic and can be cleaved to antiangiogenic vasoinhibins. We investigated whether circulating prolactin and vasoinhibins associate with incidence and progression of ROP. METHODS: A prospective, longitudinal, case-control study covering postnatal weeks 1 to 9 measured serum prolactin, vasoinhibins, and vascular endothelial growth factor (VEGF) weekly in 90 premature infants diagnosed as ROP or control. RESULTS:Prolactin levels were higher in ROP than in control patients before (106.2 ± 11.3 (SEM) vs. 64.7 ± 4.9 ng/ml, postnatal week 1) and during (120.6 ± 10 vs. 84.7 ± 7.5ng/ml, postnatal week 5) ROP diagnosis. Prolactin, but not gestational age, birth weight, Apgar score, sepsis, or ventilation time, correlated with ROP. The relative risk (RR) of developing ROP increased if Prolactin (PRL) levels were higher than thresholds of 80 ng/ml (RR = 1.55, 95% CI: 1.06-2.28), 100 ng/ml (RR = 1.63, 95% CI: 1.14-2.34), or 120 ng/ml (RR = 1.95, 95% CI: 1.41-2.68). Vasoinhibin levels were 39.7% higher (95% CI: 4.5-77.5) in the circulation of ROP than in control patients at postnatal week 1 and similar thereafter, whereas VEGF serum levels were always similar. CONCLUSION: High serum prolactin and vasoinhibin levels predict and may impact ROP progression.
Authors: Mayda Ramírez; Zhijian Wu; Bibiana Moreno-Carranza; Michael C Jeziorski; Edith Arnold; Nundehui Díaz-Lezama; Gonzalo Martínez de la Escalera; Peter Colosi; Carmen Clapp Journal: Invest Ophthalmol Vis Sci Date: 2011-11-21 Impact factor: 4.799
Authors: Raul Velez-Montoya; Carmen Clapp; Jose Carlos Rivera; Gerardo Garcia-Aguirre; Virgilio Morales-Cantón; Jans Fromow-Guerra; Jose Luis Guerrero-Naranjo; Hugo Quiroz-Mercado Journal: Clin Ophthalmol Date: 2010-09-07
Authors: Jakob Triebel; Thomas Bertsch; Cornelius Bollheimer; Daniel Rios-Barrera; Christy F Pearce; Michael Hüfner; Gonzalo Martínez de la Escalera; Carmen Clapp Journal: Am J Physiol Regul Integr Comp Physiol Date: 2015-08-26 Impact factor: 3.619
Authors: Carmen Clapp; Georgina Ortiz; Jose F García-Rodrigo; María G Ledesma-Colunga; Oscar F Martínez-Díaz; Norma Adán; Gonzalo Martínez de la Escalera Journal: Front Endocrinol (Lausanne) Date: 2022-06-02 Impact factor: 6.055
Authors: Jakob Triebel; Maria Ludivina Robles-Osorio; Renata Garcia-Franco; Gonzalo Martínez de la Escalera; Carmen Clapp; Thomas Bertsch Journal: Front Endocrinol (Lausanne) Date: 2017-12-11 Impact factor: 5.555
Authors: Juan Pablo Robles; Magdalena Zamora; José Luis Velasco-Bolom; Miriam Tovar; Ramón Garduño-Juárez; Thomas Bertsch; Gonzalo Martínez de la Escalera; Jakob Triebel; Carmen Clapp Journal: Sci Rep Date: 2018-11-20 Impact factor: 4.379
Authors: Ma Ludivina Robles-Osorio; Renata García-Franco; Carlos D Núñez-Amaro; Ximena Mira-Lorenzo; Paulina Ramírez-Neria; Wendy Hernández; Ellery López-Star; Thomas Bertsch; Gonzalo Martínez de la Escalera; Jakob Triebel; Carmen Clapp Journal: Front Endocrinol (Lausanne) Date: 2018-05-29 Impact factor: 5.555
Authors: Jakob Triebel; Christin J Friedrich; Andreas Leuchs; Gonzalo Martínez de la Escalera; Carmen Clapp; Thomas Bertsch Journal: Front Endocrinol (Lausanne) Date: 2017-11-06 Impact factor: 5.555
Authors: Carlos D Nuñez-Amaro; Aura Ileana Moreno-Vega; Elva Adan-Castro; Magdalena Zamora; Renata Garcia-Franco; Paulina Ramirez-Neria; Marlon Garcia-Roa; Yolanda Villalpando; Juan Pablo Robles; Gabriela Ramirez-Hernandez; Mariana Lopez; Jorge Sanchez; Ellery Lopez-Star; Thomas Bertsch; Gonzalo Martinez de la Escalera; Ma Ludivina Robles-Osorio; Jakob Triebel; Carmen Clapp Journal: Transl Vis Sci Technol Date: 2020-08-17 Impact factor: 3.283
Authors: Juan Pablo Robles; Magdalena Zamora; Lourdes Siqueiros-Marquez; Elva Adan-Castro; Gabriela Ramirez-Hernandez; Francisco Freinet Nuñez; Fernando Lopez-Casillas; Robert P Millar; Thomas Bertsch; Gonzalo Martínez de la Escalera; Jakob Triebel; Carmen Clapp Journal: Angiogenesis Date: 2021-06-07 Impact factor: 9.596